In The News: Department of Brain Health
UNLV and the Cleveland Clinic Lou Ruvo Center for Brain Health have received an $11.3 million federal grant for the next phase of their joint research into the causes of degenerative brain diseases such as Alzheimer’s and potential treatments.
A recent proposal that Medicare only cover Aduhelm (aducanumab) for patients with Alzheimer’s disease who are enrolled in clinical trials is needlessly restrictive, and will prevent many people from accessing a medication that may be able to help them.
Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.
The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas detailed the steps necessary to lower wasted costs from Alzheimer disease drug development and improve regulatory success.
This year has been a major year in the field of Alzheimer disease (AD), with several promising therapies moving forward and the first FDA approval in almost 2 decades.
It’s called the Chambers-Grundy Center for Transformative Neuroscience at UNLV, and the adjective in the name says it all.
The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed new data that highlights wasted expenditures from Alzheimer trials and the importance of understanding their impacts.
Pharmacological studies have attempted and failed for past decades to generate medicines that might halt the course of the illness. Now, experts claim to have reached a tipping point in Alzheimer's development.
The cause of Alzheimer’s was supposedly simple.
Alzheimer’s treatments seemed unlikely just a few months ago.
A week ago, Brigham and Women's Hospital announced it would spearhead the first human trial of a nasal spray vaccine as a protection against Alzheimer's disease, formulated to prevent or delay the progression of the disease.
Last week, Brigham and Women's Hospital announced that it would pioneer a trial using a spray drug for Alzheimer's disease.